New anticoagulant drugs

被引：91

作者：

Weitz, JI

Hirsh, J

Samama, MM

机构：

来源：

CHEST | 2004年 / 126卷 / 03期

关键词：

anticoagulants; antithrombotic drugs; profibrinolytic agents;

D O I：

10.1378/chest.126.3_suppl.265S

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

This article about new anticoagulant drugs is part of the seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The limitations of existing oral and parenteral anticoagulant agents have prompted a search for novel agents. Focusing on new anticoagulant drugs for the prevention and treatment of arterial and venous thrombosis, this article (1) reviews arterial and venous thrombogenesis, (2) discusses the regulation of coagulation, (3) describes the pathways for testing new anticoagulant agents, (4) describes new anticoagulant strategies focusing primarily on agents in phase 11 or III clinical testing, and (5) provides clinical perspective as to which of these new strategies is most likely to succeed.

引用

收藏

页码：265S / 286S

页数：22

相关论文

共 140 条

[81] Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison [J].

Lassen, MR ;

Bauer, KA ;

Eriksson, BI ;

Turpie, AGG .

LANCET, 2002, 359 (9319) :1715-1720

[82] Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement [J].

Lee, A ;

Agnelli, G ;

Büller, H ;

Ginsberg, J ;

Heit, J ;

Rote, W ;

Vlasuk, G ;

Costantini, L ;

Julian, J ;

Comp, P ;

van der Meer, J ;

Piovella, F ;

Raskob, G ;

Gent, M .

CIRCULATION, 2001, 104 (01) :74-78

[83] Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin [J].

Lefevre, G ;

Duval, M ;

Gauron, S ;

Brookman, LJ ;

Rolan, PE ;

Morris, TM ;

Piraino, AJ ;

Morgan, JM ;

Palmisano, M ;

Close, P .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :50-59

[84]

LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606

[85]

Lincoff AM, 2000, J AM COLL CARDIOL, V36, P312

[86] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention - REPLACE-2 Randomized Trial [J].

Lincoff, AM ;

Bittl, JA ;

Harrington, RA ;

Feit, F ;

Kleiman, NS ;

Jackman, JD ;

Sarembock, IJ ;

Cohen, DJ ;

Spriggs, D ;

Ebrahimi, R ;

Keren, G ;

Carr, J ;

Cohen, EA ;

Betriu, A ;

Desmet, W ;

Kereiakes, DJ ;

Rutsch, W ;

Wilcox, RG ;

de Feyter, PJ ;

Vahanian, A ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07) :853-863

[87] Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) [J].

Lincoff, AM ;

Kleiman, NS ;

Kottke-Marchant, K ;

Maierson, ES ;

Maresh, K ;

Wolski, KE ;

Topol, EJ .

AMERICAN HEART JOURNAL, 2002, 143 (05) :847-853

[88] The dynamics of thrombin formation [J].

Mann, KG ;

Butenas, S ;

Brummel, K .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :17-25

[89] An economic evaluation of activated protein C treatment for severe sepsis. [J].

Manns, BJ ;

Lee, H ;

Doig, CJ ;

Johnson, D ;

Donaldson, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :993-1000

[90] DESIGN AND CHARACTERIZATION OF HIRULOGS - A NOVEL CLASS OF BIVALENT PEPTIDE INHIBITORS OF THROMBIN [J].

MARAGANORE, JM ;

BOURDON, P ;

JABLONSKI, J ;

RAMACHANDRAN, KL ;

FENTON, JW .

BIOCHEMISTRY, 1990, 29 (30) :7095-7101

← 4 5 6 7 8 9 10 11 12 13 →